Camber Capital Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Camber Capital Management’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-291,600	Closed	-$14.7M	–	33
2019 Q1	$14.7M	Hold	291,600	–	–	0.73%	25
2018 Q4	$11.7M	Hold	291,600	–	–	0.56%	32
2018 Q3	$20.2M	Buy	291,600 +30,500	+12%	+$2.31M	0.87%	23
2018 Q2	$19.8M	Buy	+261,100	New	+$16.4M	0.76%	31
2015 Q1	–	Sell	-200,400	Closed	-$3.11M	–	46
2014 Q4	$3.11M	Buy	+200,400	New	+$2.56M	0.21%	40

Other funds holding EGRX

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return

HEC

Hudson Executive Capital New York $50.9M AUM 22.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Camber Capital Management's EGRX Position: Q2 2019 in Review

Camber Capital Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2019, closing a stake of 291,600 shares — an estimated $14.7M sold.

Camber Capital Management first reported a position in EGRX in Q4 2014 and held it in 5 quarters. The position peaked at $20.2M in Q3 2018. 180 funds tracked by Wall St. Rank hold EGRX as of Q2 2019.

Camber Capital Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
Camber Capital Management sold 291,600 Eagle Pharmaceuticals, Inc. shares in Q2 2019, an estimated $14.7M.
Camber Capital Management first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2014 and held it in 5 quarters.
Camber Capital Management's Eagle Pharmaceuticals, Inc. position peaked at $20.2M in Q3 2018.
180 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2019.

Based on Camber Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.